In this episode we interview Dr. Stephanie Faubion about hormone therapy for the treatment of menopause symptoms. We cover the new position statement released by NAMS about hormone therapy, what changed since the last position statement, how clinicians can frame conversations about hormone therapy, and where clinicians can learn more about providing hormone therapy. You can also still register for the NAMS Conference that is being held in Atlanta October 12-15, 2022.
Interview Questions
1. Can you start by explaining to our listeners what is the North American Menopause Society or NAMS and what are the goals of NAMS?
2. What gaps do you feel exist in menopause and symptom management?
3. During our phone conversation, you shared that there is a movement from calling it hormone replacement therapy to just hormone therapy. Can you share more about this movement and why it is happening?
4. NAMS recently released a new position statement on hormone therapy, which we will be sure to include the link for on our webpage. Can you share with us what fueled the updated position and what changes were made from the 2017 position statement?
5. The position statement states, “Personalization with shared decision-making remains key, with periodic reevaluation to determine an individual woman’s benefit-risk profile.” Can you share with our listeners how they can frame or ask questions to personalize and create shared decision-making around hormone therapy?
6. In our clinical experience, we have found that some providers are reluctant to prescribe hormone therapy. Why do you feel that is the case and what advice do you for reluctant providers?
7. What communication tips do you have for clinicians so that patients do not feel like their symptoms of menopause are being dismissed or minimized.
8. We have a growing number of listeners who do not identify as clinicians; what would you like to share with these folks who may be considering hormone therapy to help manage symptoms of menopause?
9. Where can listeners go to learn more about NAMS and hormone therapy?
